Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-5491.33%
operating margin TTM
-5683.61%
revenue TTM
1.16 Million
revenue per share TTM
0.04$
valuation ratios | |
|---|---|
| pe ratio | -0.35 |
| peg ratio | 0.04 |
| price to book ratio | 0.69 |
| price to sales ratio | 16.71 |
| enterprise value multiple | -0.74 |
| price fair value | 0.69 |
profitability ratios | |
|---|---|
| gross profit margin | 41.13% |
| operating profit margin | -5683.61% |
| pretax profit margin | -5490.78% |
| net profit margin | -5491.33% |
| return on assets | -143.49% |
| return on equity | -133.02% |
| return on capital employed | -201.64% |
liquidity ratios | |
|---|---|
| current ratio | 3.67 |
| quick ratio | 3.67 |
| cash ratio | 2.41 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 750.03 |
| cash conversion cycle | -750.03 |
| receivables turnover | 0.00 |
| payables turnover | 0.49 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.02 |
| debt equity ratio | 0.03 |
| long term debt to capitalization | 0.01 |
| total debt to capitalization | 0.03 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -63.64 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.75 |
| cash per share | 1.19 |
| operating cash flow per share | -1.74 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -63.64 |
| short term coverage ratios | -83.57 |
| capital expenditure coverage ratio | -349.66 |
Frequently Asked Questions
When was the last time VistaGen Therapeutics, Inc. (NASDAQ:VTGN) reported earnings?
VistaGen Therapeutics, Inc. (VTGN) published its most recent earnings results on 15-06-2026.
What is VistaGen Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. VistaGen Therapeutics, Inc. (NASDAQ:VTGN)'s trailing twelve months ROE is -133.02%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. VistaGen Therapeutics, Inc. (VTGN) currently has a ROA of -143.49%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did VTGN's net profit margin stand at?
VTGN reported a profit margin of -5491.33% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is VTGN's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 3.67 in the most recent quarter. The quick ratio stood at 3.67, with a Debt/Eq ratio of 0.03.